DUBLIN--(BUSINESS WIRE)--
Dublin - Research and Markets (http://www.researchandmarkets.com/research/a76fe7b1/approval_of_kalyde) has announced the addition of GlobalData's new company profile "Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation" to their offering.
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation:
The report is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with G551D mutation. The report provides insights on the product clinical information and how it will bring new hopes for the CF patients.
Scope:
- Epidemiology
- Survival
- Current Therapy Options
- Unmet Need
- Kalydeco - First Disease-Modifying CF Therapy
- Clinical Trial Details 3
- Cystic Fibrosis Therapeutic Market - Drivers and Barriers
Reasons to Buy:
- Inputs on the current treatment options available and the clinical study of the drug.
- Business strategies development by understanding the current trends and future tends that will driving the global CF therapeutics market. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- How this breakthrough treatment for CF patients with G551D mutation brings new hope.
Key Topics Covered:
1 List of Figures
2 Summary
3 Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation
3.1 Cystic Fibrosis Overview
3.1.1 Disease Overview
3.1.2 Epidemiology
3.1.3 Survival
3.1.4 Current Therapy Options
3.1.5 Unmet Need
3.1.6 Kalydeco - First Disease-Modifying CF Therapy
3.1.7 Clinical Trial Details
3.1.8 Cystic Fibrosis Therapeutic Market
3.1.9 Cystic Fibrosis Therapeutic Market - Drivers and Barriers
4 Appendix
Figure 1: CFTR Channel Mutation and Regulation of the Chloride Channel
For more information visit http://www.researchandmarkets.com/research/a76fe7b1/approval_of_kalyde
Source: GlobalData